Tan, R., Kallay, M., (PI), InterMune Pharmaceuticals, A Randomized, Double-blind, Placebo-controlled Phase III Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis 2000-2002.
Tan, R., Kallay, M., (PI), Wyeth Pharmaceuticals, A Double-blind, Parallel, Placebo-controlled Randomized Study of the Efficacy and Safety Of Etanercept in Patients with Idiopathic Pulmonary Fibrosis, 2003 -- 2004
Tan, R., Kallay, M., (PI), Intermune Pharmaceuticals, Effects of Interferon Gamma 1b on Biomarkers in Patients with Idiopathic Pulmonary Fibrosis: a Randomized, Double-blind Study, 2002.
Tan, R., Kallay, M., (PI), Intermune Pharmaceuticals, A Randomized, Double-blind, Placebo-controlled, Phase III Study of the Safety and Efficacy of Interferon Gamma – 1b in Patients with Idiopathic Pulmonary Fibrosis, 2004.
Tan, R., Kallay, M., (PI), Intermune Pharmaceuticals, A Randomized, Double-Blind, Placebo-controlled, Phase III Study of the Safety and Efficacy of Perfenidone in patients with Idiopathic Pulmonary Fibrosis. Initiation March, 2006
Tan, R., Kallay, M., (PI), Actelion Pharmaceuticals, Effects of bosentan on morbidity and mortality in patients with idiopathic Pulmicort fibrosis-a multicentered, double blinded, randomized, placebo-controlled, parallel group, event driven, sequential, phase III study. Initiation February, 2007
Tan, R., Kallay, M., (PI), PANTHER-IPF – Prednisone, Azathioprine, and N-acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis, A Randomized, Double Blind, Placebo Controlled Trial. Initiation September, 2009.
Tan, R., Kallay, M., (PI), PIPF-016 – A Randomized Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Initiation June, 2011.
Gilead – GS-US-322-0207 – A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab in Subjects with Idiopathic Pulmonary Fibrosis, October, 2012.
Genentech – GB28547 RIFF - A Phase II, Randomized, Double-blind, Placebo-controlled, Study to assess the Efficacy and Safety of Llebrikizumab in Patients with Idiopathic Pulmonary Fibrosis, April, 2013.
Bristol Myers Squibb – BMS - IM136003 – Safety and Efficacy of A Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis, August, 2013.
DiGiovanni BF, Diliberto FE, Tome J, Tan RK, Nawoczenski DA: R15 AREA Grant,"A Prospective Analysis of Biomechanical Foot Function Following an Isolated Gastrocnemius Recession for Achilles Tendinopathy, September, 2014.